Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
German CLL Study Group
ClinicalTrials.gov Identifier:
NCT00634881
First received: March 12, 2008
Last updated: September 23, 2016
Last verified: September 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2010
  Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)